Document is current
Any future updates will be listed below
-
Authors
Gallais, Fanny
Ysebaert, Loïc
Despas, Fabien
De Barros, Sandra
Dupré, Loïc
Quillet-Mary, Anne
Protin, Caroline
Thomas, Fabienne
Obéric, Lucie
Allal, Ben
Chatelut, Etienne
White-Koning, Mélanie
-
Funding
Funding for this research was provided by:
Agence Nationale de Sécurité du Médicament et des Produits de Santé
Agence Nationale de la Recherche (CAPTOR PHUC-001)
Institut National Du Cancer (C15092BS)
- License Information
-
More Information
Article History
First Online: 24 April 2020
Compliance with Ethical Standards
:
: This study has been supported by the French National Drug Agency (ANSM), the French National Research Agency (ANR, project CAPTOR PHUC-001), and the AVIESAN, INCa and INSERM Plan Cancer program (project C15092BS).
: Loïc Ysebaert received grant support and honorarium fees from Roche, Abbvie, Gilead and Janssen, but not in the scope of the present study. Lucie Obéric received honorarium fees from Roche and Janssen, but not in the scope of the present study. Fanny Gallais, Fabien Despas, Sandra De Barros, Loïc Dupré, Anne Quillet-Mary, Caroline Protin, Fabienne Thomas, Ben Allal, Etienne Chatelut and Mélanie White-Koning have no conflicts of interest that are directly relevant to the content of this article.
: The study was conducted in compliance with ethical standards.
: All patients gave their written informed consent.
